Skin Metastases from Hepatobiliary Cancers: A Systematic Review

A rare but revealing complication of liver and bile-duct cancers is drawing renewed attention to the skin, where malignant cells can sometimes appear as visible signs of disease spreading through the body. A systematic review published in Archives of Dermatological Research examines cutaneous metastases associated with hepatobiliary cancers—malignancies arising in the liver, gallbladder or bile ducts. The research letter, led by Nicholas Belair and colleagues, brings together clinical evidence on a phenomenon that is uncommon but medically important: the arrival of cancer cells in skin or tissue immediately beneath it. Such lesions may resemble ordinary dermatological problems, yet they can provide a rapid clue that an internal cancer is present, progressing or, in some cases, recurring after treatment. The review’s subject sits at the intersection of oncology, gastroenterology and dermatology, highlighting how a change on the body’s surface can reflect complex biological events deep within the abdomen.

Hepatobiliary cancers include several distinct diseases with different cellular origins and patterns of spread. Hepatocellular carcinoma begins primarily in liver cells, whereas cholangiocarcinoma arises from the epithelial cells lining the bile ducts. Other cancers may originate in the gallbladder or related structures. Despite their differences, these tumors can disseminate when malignant cells detach from the primary mass, invade blood vessels or lymphatic channels and survive transport to distant organs. The skin is not usually the first destination for such cells. Metastatic deposits more commonly involve organs such as the lungs, bones, lymph nodes or peritoneal surfaces, depending on the cancer type. When tumor cells establish themselves in cutaneous tissue, they must exit circulation, cross vessel walls, adapt to a new extracellular environment and recruit nutrients sufficient for growth. This sequence is biologically demanding, which helps explain why skin metastases are rare even in advanced cancers. Their rarity, however, does not make them trivial: they may signal extensive metastatic capacity.

Clinically, a cutaneous metastasis can be deceptively ordinary. It may present as a firm nodule, a lump beneath the skin, a plaque or an ulcerated lesion. Color and surface appearance can vary, and the lesion may be painless, tender, inflamed or prone to bleeding. Because many benign conditions—including cysts, lipomas, inflamed follicles and vascular growths—can look similar, appearance alone cannot establish the diagnosis. In a patient already known to have hepatobiliary cancer, a new rapidly enlarging skin lesion warrants particular attention, especially if it develops near a surgical scar, a biopsy site or another region involved in medical procedures. Yet not every lesion in such a patient is metastatic. The central diagnostic challenge is therefore to connect the clinical observation with tissue evidence rather than infer malignancy from appearance alone.

The route by which liver or bile-duct cancer reaches the skin can vary. Hematogenous dissemination, in which cells travel through the bloodstream, is a leading biological explanation. Tumor cells may enter the portal or systemic circulation, pass through vascular networks and eventually lodge in small vessels supplying the skin. Lymphatic spread provides another possible pathway, while direct extension can occur when a tumor grows into adjacent tissues. A special mechanism is implantation: malignant cells may be mechanically transferred to a wound or procedural tract, where they later proliferate. One cited report in the review describes non-iatrogenic implantation of cutaneous metastasis from hepatocellular carcinoma, while other literature has considered lesions arising after interventions. These routes are not merely theoretical distinctions. Understanding them can influence how clinicians interpret the location and timing of a lesion, assess the extent of disease and consider whether local treatment or broader systemic therapy is appropriate.

Confirming a cutaneous metastasis generally requires a biopsy. During this procedure, a sample of the lesion is removed and examined under a microscope. Pathologists look for malignant architecture and cellular features that are compatible with the suspected primary tumor. Histology may be supplemented by immunohistochemistry, a technique that uses antibodies to detect proteins within tumor cells. In hepatocellular carcinoma, markers such as Hep Par 1 can support a liver-cell origin when interpreted alongside morphology and the patient’s clinical history. The source material cites a case in which fine-needle aspiration cytology and Hep Par 1 immunopositivity helped diagnose a cutaneous metastasis of hepatocellular carcinoma. Cytology examines individual cells obtained with a thin needle, whereas a core or excisional biopsy preserves more of the tissue structure. Neither immunostaining nor cytology should be interpreted in isolation: the most reliable diagnosis combines pathology, imaging, laboratory findings and knowledge of any previously diagnosed cancer.

The review also underscores why these lesions may carry significance beyond the skin. A metastatic deposit demonstrates that tumor cells have acquired the ability to leave their original environment and colonize a distant site. In cancer biology, this process involves several stages, including invasion, intravasation into vessels, survival in circulation, extravasation into a new tissue and adaptation to local signals. The “seed and soil” concept describes how successful metastasis depends not only on the properties of the cancer cell, or seed, but also on whether a distant tissue provides a supportive soil. Skin contains fibroblasts, immune cells, blood vessels and extracellular-matrix proteins that can either resist or support colonization. A visible lesion may therefore represent the endpoint of a highly selective evolutionary process. At the same time, the presence of a skin metastasis does not by itself reveal the full burden of disease. Imaging and staging remain necessary to determine whether additional organs are involved.

For clinicians, the practical message is one of vigilance without overreaction. A new lesion in someone with hepatobiliary cancer should enter the diagnostic conversation, but it should not automatically be labeled a metastasis. Timing, growth rate, anatomical distribution and symptoms can help determine how urgently it should be investigated. In some patients, a cutaneous lesion may be the first outward sign of an otherwise unsuspected internal malignancy. In others, it may reveal recurrence after an interval in which the primary tumor appeared controlled. The lesion can also create symptoms of its own, including pain, ulceration, bleeding or infection, and those problems may require local management even when treatment is primarily systemic. Depending on a patient’s overall condition and the extent of disease, care may involve surgery, radiation, drug therapy or palliative measures. The review does not provide treatment recommendations in the accessible article information, so therapeutic decisions must be based on individualized oncology assessment rather than on the existence of a skin lesion alone.

The evidence assembled by Belair, Mansour, Kasmikha, Kessler and Daveluy also points to the value of collaboration across specialties. Dermatologists are often the physicians who recognize an unusual nodule or plaque, while oncologists, hepatologists, surgeons, radiologists and pathologists supply the broader context needed to interpret it. A dermatologist may identify the lesion’s morphology and select an appropriate biopsy method; a pathologist may compare its microscopic and immunohistochemical profile with tissue from a known primary tumor; and imaging specialists may search for other metastatic sites. This chain of expertise matters particularly because hepatobiliary cancers can be clinically silent or difficult to detect until they are advanced. The authors report that they developed the project and collected data together, with the manuscript written and reviewed collaboratively. Their compiled data were made available in a viewable spreadsheet, offering a resource for further examination of the reported cases and patterns represented in the review.

Although cutaneous metastases remain an unusual manifestation of hepatobiliary cancer, their visibility gives them unusual power as clinical signals. A small lesion on the scalp, trunk, abdomen or extremity may encode information about the behavior of a tumor that cannot be seen directly. The phenomenon also illustrates a broader principle of modern medicine: organs cannot always be considered in isolation. The skin can reflect systemic inflammation, immune dysfunction, vascular disease—and, rarely, the movement of malignant cells from distant tissues. By consolidating reports of skin involvement in hepatobiliary cancers, the new review draws attention to a diagnostic blind spot that can be overlooked precisely because it is uncommon. Its significance is not that every skin growth heralds advanced cancer, but that unexplained or changing lesions deserve careful assessment, particularly when they arise in a patient with a known or possible internal malignancy. In those cases, dermatology may become the first place where a hidden change in cancer biology becomes visible.